WuXi PharmaTech (Cayman) WX
-
New Morningstar Analyst Report - WuXi PharmaTech ( Cayman ), Inc.
Increased offshoring and outsourcing of R&D is driving double-digit expansion for WuXi.
-
WuXi PharmaTech ( Cayman ), Inc. WX Q1 2012 Earnings Call Transcript
Ladies and gentlemen thank you for standing by and welcome to the WuXi PharmaTech Q1 2012 Earnings Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. I must advise you that this conference is being ...
-
WuXi PharmaTech ( WX ): Q1 EPS of $0.33 beats by $0.07. Revenue of $118M (+26.1% Y/Y) beats by $4M. (PR)
WuXi PharmaTech ( WX ): Q1 EPS of $0.33 beats by $0.07 . Revenue of $118M (+26.1% Y/Y) beats by $4M . ( PR ) Post your comment!
-
3 Biotechs To Watch This Week
By Jessica King Holden : With the release of earnings this week and recent news, there are three biotechs that are on my radar. Two of the three are playing for the home run and will not likely blow away the market with earnings reports but will garner attention in coming weeks. The other offers a
-
Are Pharmaceuticals Set For A Run?
By Villi Grdovich : WHAT DO THE INDICTORS INDICATE? The Market Turmoil indicator, as shown below, has essentially gone to zero. My interpretation is that the market is back to normal functioning. This indicates that high beta stocks should still be on the radar, however opinions vary as to how ...
-
Manufacturing Services Boost Growth and Support Earnings During WuXi's Fourth Quarter
We are keeping our fair value estimate intact for WuXi WX after reviewing the company's fourth-quarter and full-year results, which were largely in line with our expectations. Fourth …
-
WuXi PharmaTech ( Cayman ), Inc. WX Q4 2011 Earnings Call Transcript
Ladies and gentlemen thank you for standing by and welcome to the WuXi PharmaTech Q4 2011 Earnings Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. I must advise you that this conference is being ...
-
WuXi PharmaTech ( WX ): Q4 EPS of $0.31 beats by $0.05. Revenue of $108.5M (+22.5% Y/Y) beats by $2M. Shares +0.4% AH. (PR)
WuXi PharmaTech ( WX ): Q4 EPS of $0.31 beats by $0.05 . Revenue of $108.5M (+22.5% Y/Y) beats by $2M . Shares +0.4% AH. ( PR ) Post your comment!
-
Are WuXi PharmaTech and ShangPharma M&A Targets?
By ChinaBio Today : WuXi PharmaTech (NYSE: WX ) and ShangPharma (NYSE: SHP ) are both attractive M&A targets, according to a Bloomberg News article (see article ). Both …
-
Contract Research Organizations Still On Sale As Industry Rebounds
By Morningstar : By Lauren Migliore We think the contract research organization (CRO) industry is on the rebound, as evidenced by a resurgence in new business activity and revenue growth during the last year. Widespread top-line growth that began in the second quarter continued into the third; on